AMG 509 (Xaluritamig): update on this immunotherapy for mCRPC

[Maxone73]

They published the first findings on Cancer Discovery.

"Efficacy as measured both by PSA and objective response by RECIST were encouraging in this heavily pretreated mCRPC population, and responses occurred with greater frequency in the higher-dose cohorts. PSA declines were seen starting with 0.1 mg xaluritamig, with 49% of patients achieving confirmed PSA50 responses and 28% of patients with PSA90 responses. At higher doses, responses were achieved in 41% of RECIST-evaluable patients. A relevant number of patients remained on treatment beyond 6 months in the higher-dose cohorts. As patients in the higher-dose cohorts had a limited time on the study [median (range) follow-up, 6.7 (0.5–20.9) months], limited conclusions on the durability of these responses can be made at this time, although preliminary DOR assessment is promising. It remains to be seen whether the PSA responses observed in patients with non–RECIST measurable disease will also translate to longer-term clinical benefit."

aacrjournals.org/cancerdisc...

[ellie2211]

how long would this take to make it available

[Maxone73 in reply to ellie2211]

To the market, considering no fast track from FDA (this could change when we have the final results of phase one, which are imminent) from phase 2 to market around 6 years still to go.